Pharmaceutical

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

Health Canada has issued a Notice of Compliance (NOC) for Johnson & Johnson’s (J&J) CARVYKTI for multiple myeloma treatment.

Nov 23, 2024 - 06:00
Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma
Health Canada has issued a Notice of Compliance (NOC) for Johnson & Johnson’s (J&J) CARVYKTI for multiple myeloma treatment.
Read the original article

Tags:

Previous Article

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl

Next Article

Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biogen to acquire Reata Pharmaceuticals in $7 billion deal

STAT+: Biogen to acquire Reata Pharmaceuticals in $7 bi...

Jul 28, 2023

Gilead Sciences reports net income rise in Q2 2024

Gilead Sciences reports net income rise in Q2 2024

Aug 11, 2024

STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more

STAT+: Pharmalittle: We’re reading about Moderna’s RSV ...

Feb 13, 2024